Federated Hermes’s Neurogene NGNE Stock Holding History

Federated Hermes’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-78	Closed	-$1.29K	–	2165
2023 Q2	$1.29K	Sell	78 -17	-18%	-$279	﹤0.01%	2015
2023 Q1	$1.33K	Sell	95 -130	-58%	-$1.52K	﹤0.01%	2029
2022 Q4	$2.29K	Buy	225 +10	+5%	+$103	﹤0.01%	1994
2022 Q3	$3K	Buy	215 +4	+2%	+$82	﹤0.01%	1939
2022 Q2	$4K	Buy	211 +93	+79%	+$2.27K	﹤0.01%	1916
2022 Q1	$4K	Sell	118 -1,169	-91%	-$68.2K	﹤0.01%	1979
2021 Q4	$124K	Buy	+1,287	New	+$157K	﹤0.01%	1691

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes's NGNE Position: Q3 2023 in Review

Federated Hermes sold out of Neurogene (NGNE) in Q3 2023, closing a stake of 78 shares — an estimated $1.29K sold.

Federated Hermes first reported a position in NGNE in Q4 2021 and held it in 7 quarters. The position peaked at $124K in Q4 2021. 31 funds tracked by Wall St. Rank hold NGNE as of Q3 2023.

Federated Hermes reported no remaining Neurogene position as of Q3 2023 after selling out during the quarter.
Federated Hermes sold 78 Neurogene shares in Q3 2023, an estimated $1.29K.
Federated Hermes first reported a position in Neurogene in Q4 2021 and held it in 7 quarters.
Federated Hermes's Neurogene position peaked at $124K in Q4 2021.
31 funds tracked by Wall St. Rank held Neurogene as of Q3 2023.

Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.